Accelerated Partial Breast Radiation vs Whole Breast Radiation Equal Against Breast Cancer

Accelerated Partial Breast Radiation vs Whole Breast Radiation Equal Against Breast Cancer
Promising results from the Groupe Européen de Curiethérapie European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) trial, to evaluate the effects of partial breast irradiation (PBI) administered with multicatheter interstitial brachytherapy, were presented by co-lead author Dr. Csaba Polgár at the 35th European Society for Therapeutic Radiology and Oncology (ESTRO) Conference, Turin. The new Phase III clinical data adds to the IMPORT-Low trial results, which together demonstrate the clinical equivalence of PBI and whole breast irradiation (WBI) for the treatment of early breast cancer. Accelerated partial breast irradiation with brachytherapy (APBI brachytherapy) is a treatment composed of a short course of high-dose radiation therapy delivered directly into the tumor tissue of early-stage breast cancer patients. It is delivered as part of breast conservation therapy (BCT), which consists of lumpectomy surgery followed by radiation. Whole breast irradiation (WBI) has been the traditional approach of BCT, a procedure that exposes the entire breast and surrounding tissue to radiation. APBI offers three main advantages over WBI: reduction in radiation exposure, reduced treatment time and preservation of future organ sparing treatment options. The primary objective of the GEC-ESTRO clinical trial was to compare APBI brachytherapy to WBI with boost, in a group of patients with invasive (stage I-IIA) breast cancer or ductal carcinoma in situ (DCIS; stage 0) who underwent breast-conserving surgery. The study evaluated 1,184 patients randomized to either group. Previous results, published in
Subscribe or to access all post and page content.